A
Anushree C. Shirali
Researcher at Yale University
Publications - 37
Citations - 2046
Anushree C. Shirali is an academic researcher from Yale University. The author has contributed to research in topics: Acute kidney injury & Kidney disease. The author has an hindex of 18, co-authored 31 publications receiving 1556 citations. Previous affiliations of Anushree C. Shirali include New York Medical College.
Papers
More filters
Journal ArticleDOI
Childhood obesity: do parents recognize this health risk?
TL;DR: It is found that most parents of overweight children fail to recognize that their child has a weight problem, and pediatricians should develop strategies to help these parents correct their misperceptions.
Journal ArticleDOI
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
TL;DR: The association of AIN with these drugs in patients with lung cancer who received anti-PD-1 antibodies raises the possibility that PD-1 inhibitor therapy may release suppression of T-cell immunity that normally permits renal tolerance of drugs known to be associated with AIN.
Journal ArticleDOI
Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study
Frank B. Cortazar,Zoe A. Kibbelaar,Ilya G. Glezerman,Ala Abudayyeh,Omar Mamlouk,Shveta S. Motwani,Naoka Murakami,Sandra M. Herrmann,Sandhya Manohar,Anushree C. Shirali,Abhijat Kitchlu,Shayan Shirazian,Amer Assal,Anitha Vijayan,Amanda DeMauro Renaghan,David I. Ortiz-Melo,Sunil Rangarajan,A. Bilal Malik,Jonathan J. Hogan,Alex Dinh,Daniel Sanghoon Shin,Kristen A. Marrone,Zain Mithani,Douglas B. Johnson,Afrooz Hosseini,Deekchha Uprety,Shreyak Sharma,Shruti Gupta,Kerry L. Reynolds,Meghan E. Sise,David E. Leaf +30 more
TL;DR: Insight is identified into the risk factors, clinical features, histopathologic findings, and renal and overall outcomes in patients with immune checkpoint inhibitor-associated AKI.
Journal ArticleDOI
Drug-induced impairment of renal function
TL;DR: This article will review those drugs that are associated with impaired renal function and provide an overview of nephrotoxic drugs that a treating physician is most likely to encounter by focusing on pharmaceutical agents that are currently in clinical practice.
Journal ArticleDOI
Management of Cardiovascular Disease in Renal Transplant Recipients
TL;DR: This review examines the data available for prevention and treatment of major risk factors contributing to cardiovascular disease in renal transplant recipients and the contribution of immunosuppressive agents to each risk factor.